One of the biggest challenges in cancer treatment is chemoresistance: Tumors that initially respond well to chemotherapy ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Gerhardt Attard, M.D., Ph.D., from University College London, and colleagues conducted a double-blind trial that evaluated combining niraparib with AAP versus placebo and AAP in mCSPC with HRR gene ...

Among patients with prostate cancer with homologous recombination repair mutations (HRRm) receiving Akeega (niraparib and ...

Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

This is a preview. Log in through your library . Abstract Homologous recombination is a key process for maintaining genome integrity and diversity. In eukaryotes, the nucleosome structure of chromatin ...

Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance.